相关实验视频
Updated: Jan 18, 2026

05:16
Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
7.3K
[-葡萄糖转运体-2 (SGLT-2) 抑制剂在术后医学:影响,副作用和当前建议]
Johannes Nienhaus1, Theresa Tenge2, Sophia Riesemann1,3
1Klinik für Anästhesiologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Moorenstr. 5, 40225, Düsseldorf, Deutschland.
Die Anaesthesiologie
|September 9, 2025
概括
-葡萄糖共运输体2 (SGLT-2) 抑制剂可以改善糖尿病,心脏和脏疾病的结果,但会带来酸性的风险. 经营管理需要个性化策略,因为风险和指导有限.
科学领域:
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
背景情况:
- -葡萄糖共运输体2 (SGLT-2) 抑制剂广泛用于糖尿病,心力衰竭和脏疾病.
- 这些药物增加尿路葡萄糖分泌,改善血糖控制和心血管结果.
- 然而,SGLT-2抑制剂与尿路感染,脱水和罕见但严重的euglycemic ketoacidosis等风险有关.
研究的目的:
- 审查SGLT-2抑制剂的作用和副作用.
- 总结目前对接受SGLT-2抑制剂的患者术后管理的建议.
- 突出在术后护理中面临的挑战和需要个性化策略.
主要方法:
- 对SGLT-2抑制剂的随机试验和病例报告的文献综述.
- 分析当前的国际指导方针和专家建议.
- 综合有关外科手术期间风险和管理策略的数据.
主要成果:
- SGLT-2 抑制剂具有显著的益处,但存在术后酸性脂肪酸症的风险,这是一个难以检测的并发症.
- 目前的指导方针建议在手术前不服用SGLT-2抑制剂,但这可能对心力衰竭患者有害.
- 一个适合所有人的方法不适合;需要个性化,风险分层的策略.
结论:
- 对SGLT-2抑制剂的周术管理是复杂的,特别是在紧急情况下.
- 考虑手术风险,禁食和子监测的个性化策略至关重要.
- 需要进一步的研究,以明确指导手术后重新启动SGLT-2抑制剂.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
526
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
526
Glucose Transporters
27.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
588
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
588
Secondary Active Transport
137.2K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
137.2K
Secondary Active Transport
9.3K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
9.3K
Oral Hypoglycemic Agents: Glinides
601
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
601

